

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
------------------	----------------

NATURE OF CONVEYANCE:	Asset Purchase Agreement
-----------------------	--------------------------

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Xtrana, Inc.		11/09/2001	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	Trinity Biotech plc
Street Address:	IDA Business Park
City:	Bray County, Wicklow
State/Country:	IRELAND
Entity Type:	public limited company: IRELAND

PROPERTY NUMBERS Total: 7

Property Type	Number	Word Mark
Registration Number:	2269735	AUTO-DIMER
Registration Number:	2075466	BIOCLOT
Registration Number:	1952443	BIOPOOL
Registration Number:	1600163	MINUTEX
Registration Number:	1600638	MINUTEX
Registration Number:	2757763	SPECTROLYSE
Registration Number:	1592653	TINTELIZE

CORRESPONDENCE DATA

Fax Number: (404)815-6555
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 404-815-6500
 Email: tadmin@kilpatrickstockton.com
 Correspondent Name: William H. Brewster
 Address Line 1: 1100 Peachtree Street, Suite 2800
 Address Line 4: Atlanta, GEORGIA 30309

OP \$190.00 2269735

DOMESTIC REPRESENTATIVE

Name: William H. Brewster
Address Line 1: 1100 Peachtree Street, Suite 2800
Address Line 4: Atlanta, GEORGIA 30309

NAME OF SUBMITTER:	James A. Trigg
Signature:	/james a. trigg/
Date:	08/24/2005

Total Attachments: 5
source=Xtrana Asset Purchase Agreement#page1.tif
source=Xtrana Asset Purchase Agreement#page2.tif
source=Xtrana Asset Purchase Agreement#page3.tif
source=Xtrana Asset Purchase Agreement#page4.tif
source=Xtrana Asset Purchase Agreement#page5.tif

ASSET PURCHASE AGREEMENT

THIS AGREEMENT is made as of November 9, 2001 by and between TRINITY BIOTECH PLC, an Irish corporation ("Buyer") and XTRANA, INC., formerly known as Biopool International Inc., a Delaware corporation ("Seller").

RECITALS

Seller wishes to sell and Buyer wishes to purchase the Hemostasis business segment of Seller (including all goodwill related thereto), consisting of the Purchased Assets (as defined in Section 1.01, below) and the Assumed Liabilities (defined in Section 1.03, below), all of which shall be collectively referred to herein as the "Business."

AGREEMENT

NOW, THEREFORE, in consideration of the mutual covenants, representation, warranties and agreements hereinafter set forth, and intending to be legally bound hereby, the parties agree as follows:

ARTICLE I

SALE OF ASSETS AND TERMS OF PAYMENT

1.01 Assets Being Sold (the "Purchased Assets"). Seller agrees to sell and Buyer agrees to purchase, at the Closing (as defined in Section 7.01 hereof), all of those assets of Seller that are used or usable primarily in connection with Seller's operation of the Business as they shall exist on the Closing Date (as defined in Section 7.01 hereof), except for the Retained Assets (as defined in Section 1.02 hereof), including without limitation the following assets:

(a) **Contracts and Commitments.** Subject to the provisions of Section 1.09 hereof, all of the right, title and interest of Seller and Biopool, as defined below, in, to and under those contracts, agreements, commitments and understandings of Seller and Biopool related to the Business that are listed in Schedule 1.01(a);

(b) **Proprietary Rights.**

(i) **Patents, Trademarks and Related Assets.** Those United States and foreign patents, trademarks, service marks, domain names, including any applications therefor, that are listed in Schedule 1.01(b) hereto, and all copyrights of Seller and Biopool used or usable primarily in connection with Seller's operation of the Business, including, without limitation, all content included on Seller's website located at www.xtrana.com that consists of information, data, copyrights or other materials used primarily in connection with Sellers' operation of the Business ("Proprietary Rights");

(ii) **Technical Know-how.** All proprietary and other technical

IN WITNESS WHEREOF, the parties have each caused this Agreement to be executed by their duly authorized officers as of the date first above written.

TRINITY BIOTECH PLC

By: 

Name: MAURICE HICKEY

Title: C.F.O.

XTRANA, INC.

By: _____

Name:


Title:

IN WITNESS WHEREOF, the parties have each caused this Agreement to be executed by their duly authorized officers as of the date first above written.

TRINITY BIOTECH PLC

By: _____
Name:
Title:

XTRANA, INC.

By:  _____
Name: Timothy J. Dahltop
Title: Chief Executive Officer

**SCHEDULES
TO
ASSET PURCHASE AGREEMENT**

Schedule 1.01(b) – Proprietary Rights.

1. Patents and Trademarks: (Initial due diligence package – Item A.4)

VENTURA

Country	Title	Appl. Type/Status	Filing Date/ Serial No.	Issue Date Patent/TM No.
PCT	Solid Phase Analysis Method	Nat'l Phase Entered – All Nat'l Phase Applications Abandoned	4/15/1987 PCT/US87/00876	
PCT	Fibrin-Binding Compound and Method	Nat'l Phase Entered – All Nat'l Phase Applications Abandoned	7/1/1988 PCT/US88/02276	
PCT	A Color-Coded Solid Phase Analysis Method	Nat'l Phase Entered – All Nat'l Phase Applications Abandoned	7/1/1988 US88/02275	
PCT	Improved Assays for t-Plasminogen Activator and Plasminogen Activator Inhibitor	Nat'l Phase Entered – All Nat'l Phase Applications Abandoned	7/5/1988 US88/02277	
US	Improved Assays for Plasminogen Activator Inhibitor and Soluble Fibrin	Issued	8/9/1989 07/391.744	5/19/1992 5.114.845
US	Method of Performing Tissue Plasminogen Activator Assay	Issued	8/11/1989 07/392.684	12/29/1992 5.175.087
Belgium	Method for Measuring tPA, ATIII, and Soluble Fibrin	Granted	8/17/1993 93113125.4	
Switzerland	Method for Measuring tPA, ATIII, and Soluble Fibrin	Granted	8/17/1993 93113125.4	
Germany	Method for Measuring tPA, ATIII, and Soluble Fibrin	Granted	8/17/1993 93113125.4	
EPO	Method for Measuring tPA, ATIII, and Soluble Fibrin	Granted	8/17/1993 E185.376	10/6/1999 0576038
France	Method for Measuring tPA, ATIII, and Soluble Fibrin	Granted	8/17/1993 93113125.4	
Great Britain	Method for Measuring tPA, ATIII, and Soluble Fibrin	Granted	8/17/1993 93113125.4	
Italy	Method for Measuring tPA, ATIII, and Soluble Fibrin	Granted	12/12/1999 39428BE/99	
Japan	Improved Assays for t-Plasminogen Activator and Plasminogen Activator Inhibitor	Granted	7/5/1988 63-506985	10/24/1997 2710376
Netherlands	Method for Measuring tPA, ATIII, and Soluble Fibrin	Granted	8/17/1993 93113125.4	
Sweden	Method for Measuring tPA, ATIII, and Soluble Fibrin	Granted	8/17/1993 93113125.4	
US	TintElize	TM Registered	8/10/1989 73/818.474	4/24/1990 1.592.653
US	Minutex	TM Registered	9/5/1989 73/823.522	6/12/1990 1.600.638
US	Minutex	TM Registered	9/5/1989 73/823.119	6/12/1990 1.600.163

Country	Title	Appl. Type/Status	Filing Date/ Serial No.	Issue Date Patent/TM No.
US	Bioclot	TM Registered	5/13/1996 75/102.974	7/1/1997 2.075.466

**SCHEDULES
TO
ASSET PURCHASE AGREEMENT**

US	Sure-Urine	TM Pending	7/30/1996 75/142.184	7/29/1997 2.083.833
US	Auto-Dimer	TM Registered	10/1/1997 75/367.106	8/10/1999 2.269.735
European	Auto-Dimer	TM Registered	1/14/1998 731885	4/29/1999 731885
Japan	Auto-Dimer	TM Registered	1/14/1998 10-2044	3/19/1999 4252967
Benelux	Acticlot	TM Registered		445368
Germany	Acticlot	TM Registered		1137286
France	Acticlot	TM Registered		909122
Italy	Acticlot	TM Registered	520.206	1520206
Germany	Acticlot	Published	9/10/1999 39955986.8	3/9/2000 39955986
Benelux	Actichrome	TM Registered	2/16/1988 711922	442001
Germany	Actichrome	TM Registered		1137287
France	Actichrome	TM Registered		1484273
Italy	Actichrome	TM Registered		520205
Germany	Actichrome	TM Pending	9/10/1999 39955984.1/05	3/9/2000 39955984
US	Spectrolyse	TM Pending	6/26/1998 75/509.467	
US	Biopool*	TM Registered	7/8/1994 74-547.181	1/30/1996 1.952.443

*8/20/01 Document Request List - Item 9.1

SWEDEN

Country	Title	Appl. Type/Status	Filing Date/ Reg. Date	Appl. No. / Reg. No.
China	Biopool - Class 5	TM/A	2001-04-16	2001060369
Sweden	Biopool Classes 1,42	TM / Reg	1986-04-30 1989-11-03	86-3429 215 007
Sweden	Desafib	TM / Reg	1987-04-01 1988-11-25	87-2594 212 497